Literature DB >> 18681884

Further experience of using azathioprine in the treatment of severe atopic dermatitis.

R Hughes1, P Collins, S Rogers.   

Abstract

Atopic dermatitis (AD) is a common disease. Severe AD has a significant effect on quality of life and is difficult to treat. We have previously reported 10 patients treated with azathioprine over a 7-year period, to good effect. We have now treated 37 patients over 18 years, and report our findings. The aim of the study was to review the efficacy and safety of azathioprine as a long-term treatment for severe atopic eczema. Patients who began treatment between 1987 and 2005 were identified. The dose and number of courses of azathioprine, duration of treatment, treatment response, and adverse events were recorded up to June 2006. In total, 37 patients were treated with azathioprine. Of these, 15 (40.5%) achieved remission in a median period of 5 months (range 4-29). Nine patients had an initial good response but either did not have sufficient clearance to be able to stop azathioprine, or deteriorated while on treatment over a period of 4-27 months; these were considered late failures. One patient showed no response, and five experienced reactions leading to withdrawal of the drug. Our experience with azathioprine for the treatment of severe atopic eczema, is very encouraging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18681884     DOI: 10.1111/j.1365-2230.2008.02832.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  10 in total

1.  Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis.

Authors:  Yunes Panahi; Seyyed Masoud Davoudi; Nima Madanchi; Ehsan Abolhasani
Journal:  Clin Exp Med       Date:  2011-11-19       Impact factor: 3.984

2.  The Clinical Efficacy of Azathioprine in Korean Patients with Atopic Dermatitis.

Authors:  Hemin Lee; Jung U Shin; Kwang Hoon Lee
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

3.  Update on the management of chronic eczema: new approaches and emerging treatment options.

Authors:  Hobart W Walling; Brian L Swick
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-07-28

4.  The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring.

Authors:  Nicholas R Fuggle; Walter Bragoli; Anjali Mahto; Mary Glover; Anna E Martinez; Veronica A Kinsler
Journal:  J Am Acad Dermatol       Date:  2014-11-04       Impact factor: 11.527

5.  Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: A randomized controlled trial.

Authors:  Fariba Iraji; Sadaf Farhadi; Gita Faghihi; Fatemeh Mokhtari; Akram Basiri; Tohid Jafari-Koshki; Mohammad Ali Nilforoushzadeh
Journal:  Adv Biomed Res       Date:  2015-10-07

Review 6.  Systemic Treatment of Adult Atopic Dermatitis: A Review.

Authors:  Matteo Megna; Maddalena Napolitano; Cataldo Patruno; Alessia Villani; Anna Balato; Giuseppe Monfrecola; Fabio Ayala; Nicola Balato
Journal:  Dermatol Ther (Heidelb)       Date:  2016-12-26

Review 7.  Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?

Authors:  Helen Alexander; Thomas Patton; Zarif K Jabbar-Lopez; Andrea Manca; Carsten Flohr
Journal:  F1000Res       Date:  2019-01-31

8.  Topical 0.05% clobetasol cream in the treatment of chronic hand eczema: A protocol for systematic review and meta-analysis.

Authors:  Mingyi Jing; Qianying Yu; Baohua Zhu; Fan Yuan; Jie Zhang; Li Peng; Wenxia Lin; Mingling Chen
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

Review 9.  Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.

Authors:  Cho-Hsun Hsieh; Yi-Wei Huang; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-05

Review 10.  [Recommendations when switching therapy from immunosuppressive drugs to dupilumab in patients with atopic dermatitis].

Authors:  Johannes Wohlrab; Ulrich Mrowietz; Stephan Weidinger; Thomas Werfel; Andreas Wollenberg
Journal:  Hautarzt       Date:  2021-04       Impact factor: 0.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.